Hypoxic-ischemic brain injury (HIBI) is a condition affecting neonates and is a leading global cause of perinatal neurological morbidity, with limited therapeutic options. Regarding its pathogenesis, the ion channel-kinase transient receptor potential melastatin 7 (TRPM7) is a known contributor to HIBI pathology and was the focus of a recently reported study.

Researchers from Tr1x Inc. presented the development of TRX-319, a novel allogeneic regulatory T-cell therapy designed for the treatment of autoimmune disorders.

Precision Biosciences Inc. has received FDA clearance of its IND application enabling clinical trial site activation for a phase I/II trial (FUNCTION-DMD) of PBGENE-DMD for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD). The first site in the U.S. will be activated in the first half of this year.

TYK2, a Janus kinase family member, mediates signaling from pro-inflammatory cytokines such as type I interferons, IL-12 and IL-23. In multiple sclerosis (MS), chronic CNS inflammation involves glial activation and immune cell infiltration, making TYK2 inhibition a potential strategy to reduce neuroinflammation.

Patients with Parkinson’s disease (PD) frequently suffer from sleep disorders, in addition to the neurodegenerative processes associated with the disease. These disorders affect both rapid eye movement (REM) and non-REM (NREM) sleep, but the underlying mechanisms in PD patients remain largely unknown.

Researchers from the Medical University of South Carolina report the development of novel genetic mouse models that enable pericyte chemogenetic modulation, which could reduce neuronal damage and cognitive decline in Alzheimer’s disease.

Beijing Innocare Pharma Tech Co. Ltd. has gained IND clearance in China to conduct clinical trials of ICP-538, an orally administered molecular glue degrader targeting VAV1, which is a key protein downstream of T-cell and B-cell receptors. ICP-538 is being studied for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus and multiple sclerosis.